Liofilchem® Cefoperazone–Sulbactam SCF Antimicrobial Susceptibility Discs, 105 µg
Catalog No :
CAS Number :
Brand :
In Stock
Specifications:
| Application | Clinical microbiology |
| Storage Temperature | -20°C |
| Product Type | Antibiotic Disc |
| Product Brand | Liofilchem |
| Product Grade | Microbiology grade |
Liofilchem® Cefoperazone–Sulbactam (SCF) 105 µg Antimicrobial Susceptibility Discs are designed for quantitative in vitro determination of bacterial susceptibility to the combination of Cefoperazone (a third-generation cephalosporin) and Sulbactam (a β-lactamase inhibitor).
This disc diffusion test provides accurate and reproducible results for detecting bacterial resistance in Enterobacteriaceae, Pseudomonas spp., Acinetobacter spp., and other clinically relevant Gram-negative organisms. Each disc contains 105 µg of Cefoperazone–Sulbactam (2:1 ratio) and is manufactured in compliance with CLSI and EUCAST standards to ensure precision, stability, and consistency.
Key Features
- Broad-spectrum β-lactam/β-lactamase inhibitor combination for detecting resistance in Gram-negative bacteria.
- Cefoperazone–Sulbactam (2:1 ratio), 105 µg per disc.
- Standardized for Kirby–Bauer disc diffusion method.
- CLSI and EUCAST compliant for clinical diagnostic use.
- ISO 9001 and ISO 13485 certified manufacturing ensuring consistent potency and diffusion.
- Ideal for hospital, public health, and reference laboratories performing antimicrobial resistance testing.
Principle of the Method
Antimicrobial susceptibility testing (AST) using the Kirby–Bauer disc diffusion method measures the inhibition zone diameter around antibiotic-impregnated discs placed on inoculated agar (typically Mueller–Hinton Agar).
The size of the inhibition zone is compared with CLSI/EUCAST interpretive standards to determine whether the tested organism is susceptible, intermediate, or resistant to Cefoperazone–Sulbactam.
Sulbactam enhances the activity of Cefoperazone by inhibiting β-lactamases produced by resistant Gram-negative bacteria, enabling reliable detection of extended-spectrum β-lactamase (ESBL) activity.
Product Specifications
| Ref. Code | Product Description | Antibiotic Content | Packaging | Quantity |
|---|---|---|---|---|
| 9304/2 | Cefoperazone–Sulbactam (SCF) 105 µg | 105 µg | Canister | 250 Discs |
Recommended Test Conditions
- Medium: Mueller–Hinton Agar (ref. 11585 or equivalent)
- Inoculum Density: 0.5 McFarland standard
- Incubation Temperature: 35 ± 2 °C
- Incubation Time: 16–18 hours (aerobic)
- Reading: Measure diameter of inhibition zone in millimeters and interpret per CLSI/EUCAST guidelines.
Storage and Stability
- Store at 2–8 °C in a dry, tightly sealed container.
- Allow discs to equilibrate to room temperature before opening.
- Protect from humidity, heat, and light.
- Shelf life: Refer to product label (typically 24–36 months).
Quality Assurance
- Compliant with CLSI M100 and EUCAST interpretive criteria.
- Manufactured under ISO 9001 and ISO 13485 quality systems.
- Each batch tested for potency, diffusion uniformity, and accuracy.
- Supplied with a Certificate of Analysis (CoA) for traceability.
Safety and Handling
- For in vitro diagnostic use only.
- Use by qualified microbiology professionals under aseptic laboratory conditions.
- Handle all clinical isolates as potentially infectious.
- Dispose of used discs and plates according to local biosafety regulations.
Ordering Information
| Product | Ref. | Antibiotic Content | Packaging Type | Quantity |
|---|---|---|---|---|
| Liofilchem® Cefoperazone–Sulbactam (SCF) | 9304/2 | 105 µg per disc | Canister | 250 Discs |
Liofilchem® Cefoperazone–Sulbactam (SCF) 105 µg Discs provide a reliable, standardized method for determining bacterial susceptibility to Cefoperazone–Sulbactam using the Kirby–Bauer disc diffusion technique. Manufactured under stringent ISO and CLSI-compliant conditions, these discs deliver accurate, reproducible, and clinically relevant AST results, making them ideal for clinical microbiology, hospital laboratories, and antimicrobial resistance surveillance programs.
0